Worth reading
73In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
17.3
Year-on-year change in net sales (%)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6,192 million+17.3%
Operating profit¥1,150 million+59.5%
Ordinary income¥1,142 million+58.6%
Net income¥833 million+60.0%
Gross Profit Margin40.5%
Operating profit margin18.6%
Selling, general and administrative expenses¥1,357 million
Results for the three months of the current quarter
Net SalesQ4 revenue is shown in the graph, but cannot be identified because the corresponding figure is unclear
Operating profit marginQ4 operating margin is shown in the graph
Full-year earnings forecast
Net Sales
¥6,600 million
Operating profit
¥1,270 million
Ordinary income
¥1,220 million
Net income
¥890 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Achieved nearly all targets in Years 1 and 2Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue increase
¥914 million
Personnel Expenses
¥183 million
Facilities and IT
¥175 million
Depreciation and amortization
¥18 million
Other
¥108 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The forecast was prepared conservatively, taking into account difficulties in procuring components and manufacturing delays due to the situation in the Middle East and other factors, as well as the possibility of delays in new product launches. Numerical assumptions: Not disclosedNew initiatives
- Renovation of Nagoya Hospital
- Expansion into Fukuoka
- More aggressive recruitment and improved compensation for specialized personnel
- Development of a next-generation electronic medical records system
- AI utilization and the development of an animal healthcare intelligence platform
- Development of an integrated CRM platform
- Development of new products and services by テルコム
- Project to raise awareness of and promote blood donation by donor animals
Key KPIsA metric the company considers important as a management benchmark.
Number of initial consultations (referrals)
10,953 Engagements
Year on year against the same period last year+9.2%
Number of affiliated hospitals
4,779 Facility
Affiliated hospital ratio
36.6 %
Number of veterinarians providing secondary care
100 People
Segment results
Secondary Veterinary Care Services
Net Sales
¥4,514 million
Year on year against the same period last year+19.2%
Diagnostic Imaging Services
Net Sales
¥647 million
Year on year against the same period last year+16.8%
Rental and sales of veterinary medical and health management equipment (home care)
Net Sales
¥1,017 million
Year on year against the same period last year+10.0%
Medium-term management plan targets
Final yearFiscal year ending March 2027
Consolidated revenue
Original plan¥5,707 million
Revised plan¥6,200 million
Current forecast¥6,600 million
Consolidated operating profit
Original plan¥1,002 million
Revised plan¥1,040 million
Current forecast¥1,270 million
ROE
Original plan14% or higher
Revised plan14% or higher
Current forecast17.0%
Financial targets
ROE
Actual results for the fiscal year ending March 202618.5%
Forecast for the fiscal year ending March 202717.0%
Market Size / Share
Number of small-animal medical facilities
13,046 Facility
Affiliated hospital ratio
36.6 %
Number of employees
Number of veterinarians
100 People
Change during the periodUp 9 from the end of the previous fiscal year
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥6,192 million (YoY +17.3%) |
| Operating profit | ¥1,150 million (YoY +59.5%) |
| Ordinary income | ¥1,142 million (YoY +58.6%) |
| Net income | ¥833 million (YoY +60.0%) |
| Gross Profit Margin | 40.5% |
| Operating profit margin | 18.6% |
| Selling, general and administrative expenses | ¥1,357 million |
| Results for the three months of the current quarter | Net Sales Q4 revenue is shown in the graph, but cannot be identified because the corresponding figure is unclear / Operating profit margin Q4 operating margin is shown in the graph |
| Full-year earnings forecast | Net Sales ¥6,600 million / Operating profit ¥1,270 million / Ordinary income ¥1,220 million / Net income ¥890 million |
| Self-assessment against the plan | Achieved nearly all targets in Years 1 and 2 |
| Segment results | Secondary Veterinary Care Services Net Sales ¥4,514 million / Year on year against the same period last year 19.2 / Diagnostic Imaging Services Net Sales ¥647 million / Year on year against the same period last year 16.8 / Rental and sales of veterinary medical and health management equipment (home care) Net Sales ¥1,017 million / Year on year against the same period last year 10 |
| Breakdown of Factors Affecting the Change | Revenue increase ¥914 million / Personnel Expenses ¥183 million / Facilities and IT ¥175 million / Depreciation and amortization ¥18 million / Other ¥108 million |
| Key KPIs | Number of initial consultations (referrals) 10,953 Engagements / Number of affiliated hospitals 4,779 Facility / Affiliated hospital ratio 36.6 % / Number of veterinarians providing secondary care 100 People |
| Number of employees | Number of veterinarians 100 People / Change during the period Up 9 from the end of the previous fiscal year |
| Assumptions Underlying the Business Outlook | The forecast was prepared conservatively, taking into account difficulties in procuring components and manufacturing delays due to the situation in the Middle East and other factors, as well as the possibility of delays in new product launches. Numerical assumptions: Not disclosed |
| Medium-term management plan targets | Final year Fiscal year ending March 2027 / Consolidated revenue Original plan ¥5,707 million / Revised plan ¥6,200 million / Current forecast ¥6,600 million / Consolidated operating profit Original plan ¥1,002 million / Revised plan ¥1,040 million / Current forecast ¥1,270 million / ROE Original plan 14% or higher / Revised plan 14% or higher / Current forecast 17.0% |
| Financial targets | ROE Actual results for the fiscal year ending March 2026 18.5% / Forecast for the fiscal year ending March 2027 17.0% |
| Market Size / Share | Number of small-animal medical facilities 13,046 Facility / Affiliated hospital ratio 36.6 % |
| New initiatives | Renovation of Nagoya Hospital, Expansion into Fukuoka, More aggressive recruitment and improved compensation for specialized personnel, Development of a next-generation electronic medical records system, AI utilization and the development of an animal healthcare intelligence platform, Development of an integrated CRM platform, Development of new products and services by テルコム, Project to raise awareness of and promote blood donation by donor animals |
Items this document does not state (10)
Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The full-year increases in revenue and profit were driven by price revisions, a steady number of consultations, expanded treatment capacity, and improved earnings power through greater operational efficiency and higher quality of care. The fourth-quarter decline in revenue was attributable to seasonal factors, including the shorter month of February and a decline in referrals at the beginning of the year, as well as the extension of MRI replacement work at Kawasaki Main Hospital.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.